|
> Home page
Scientists alter pancreatic cells to
treat Type 1 diabetes
By Karen Kaplan, Los Angeles Times
(c) By activating one gene, researchers
can reprogram cells to produce insulin, according to a study in
the journal Cell.
NO ADSENSE ACCOUNT SELECTED FOR GOOGLE ADSENSE
A race is on to find a way to
cure Type 1 diabetes by regenerating the insulin-producing
cells in the pancreas that are lost in the disease.
Without them, the body is unable to metabolize sugar,
forcing patients to compensate by injecting themselves
with insulin several times a day.
One popular strategy has been to try to
get embryonic stem cells or induced pluripotent stem cells --
which can theoretically become any type of human cell -- to
grow into these so-called beta cells. Last year researchers
from Harvard University took a huge shortcut and transformed
normal pancreas cells into the coveted beta cells by activating
a trio of dormant genes.
On Thursday, a team of European and
American researchers showed that pancreatic cells in diabetic
mice could be reprogrammed into beta cells by turning on just
one gene, called Pax4.
NO ADSENSE ACCOUNT SELECTED FOR GOOGLE ADSENSE The scientists gave
the mice a chemical called streptozotocin that killed off their
beta cells while preserving other types of pancreatic cells.
Then they activated the Pax4 gene, which does most of its work
during fetal development.
They found that the gene converted
so-called alpha cells -- which normally made a hormone called
glucagon -- into beta cells that made insulin. Beta cell levels
were eight times higher in treated mice than in untreated
control subjects, according to the study published in Friday's
edition of the journal Cell.
For some reason that the researchers don't yet understand,
the therapy worked best on mice that were less than 1 month
old. For them, the treatment completely counteracted the
symptoms of Type 1 diabetes.
In fact, it may have worked too well, leaving the mice with
a shortage of alpha cells. Before this approach can be tried in
humans, scientists will need to figure out a safe way to turn
on the Pax4 gene -- and then find a way to shut it off.
"A lot of ifs remain before we will know whether it could be
taken to the clinic," said the study's lead author, Patrick
Collombat, a researcher at the Max Planck Institute for
Biophysical Chemistry in Germany.
But for Type 1 diabetes patients who are currently treated
with daily insulin injections, he said in a statement, this
much is clear: "We need a better treatment. We need to find a
way to regenerate beta cells."
For more information:
karen.kaplan@latimes.com
http://www.latimes.com/news/science/la-sci-diabetes8-2009aug08,0,7120515.story
Copyright 2009 Los Angeles Times
|